



ASX ANNOUNCEMENT

ACW CEO presents at Sachs 15th Annual European Life Sciences Conference

Sydney, 1 March 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) CEO Dr Steven Gourlay will give a virtual presentation to the Sachs 15th Annual European Life Sciences CEO Forum for Partnering & Investment conference today.¹

Dr Gourlay will also have the opportunity to conduct virtual business development and other stakeholder meetings during the main conference days, 1-2 March, through to the conference close on Friday 4 March. The information used for Dr Gourlay’s presentation and meetings is attached to this announcement.

The focus of Dr Gourlay’s presentation and meetings is to update the industry on recent developments in the Company’s clinical development pipeline, including:

- **Completion of the last patient visit in the XanaMIA Part A trial in Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease (AD) in February 2022, with expected cognition results timeline narrowed from Q2 2022 to April 2022**
- **Retrospective analysis of the effects of Xanamem® on “disease modifying” biomarkers using stored samples from the prior Phase 2 study in mild AD, with results expected in H2 CY2022**
- **Expansion of the Phase 2 XanaFX clinical trial for patients with Fragile X Syndrome (FXS) to include sites in North America and a new 5mg dose group, with planned enrolment increased from 50 to 75. The trial is commencing following receipt of US FDA IND approval in November 2021, and results are expected in 2023**
- **Selection of Major Depressive Disorder (MDD) as the third indication for Xanamem trials, based on a strong scientific rationale, with a randomised phase 2 clinical trial scheduled to commence in 2022. Results are expected in 2023.**

Dr Steven Gourlay, Actinogen CEO and MD, commented:

“We are delighted to update potential pharmaceutical industry partners on our expanded clinical development pipeline and its multiple near and medium-term milestones.

“It is pleasing to see strong ongoing interest and activity in the sector at the Sachs Associates European Life Sciences conference. This is especially true of the Alzheimer’s Disease field that was boosted by the 2021 accelerated approval by the FDA of the anti-amyloid antibody, Aduhelm.

¹ The fully virtual conference will be held in the Central European Time Zone.

© Xanamem is a registered trademark of Actinogen Medical Limited

“Actinogen is actively exploring the effects of its lead molecule, Xanamem, on its ability to improve cognition in a range of diseases.

“Actinogen’s clinical development pipeline is designed to fulfil our vision of making a material difference to the quality of life for people and their families living with serious neurological conditions like Alzheimer’s Disease, Fragile X Syndrome, and Depression.”

ENDS

Investors

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Michael Roberts
Investor Relations
M: +61 423 866 231
E. michael.roberts@actinogen.com.au

Media

Randal Killip
Profile for Media
M: +61 425 714 159
E. randal@profileformedia.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer’s Disease, Fragile X Syndrome, Depression and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem®

Xanamem’s novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11β-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, potentially linked to cognitive impairment and anxiety in Fragile X Syndrome, and cognitive impairment in Depression and other diseases.

The Company has studied 11β-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem’s therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place.

Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.